Brak tak Aktualny sle markers odbieranie Wymyślać Wymienny
Frontiers | Comparison of Surrogate Markers of the Type I Interferon Response and Their Ability to Mirror Disease Activity in Systemic Lupus Erythematosus
Systemic lupus erythematosus: a clinical update - Connelly - 2021 - Internal Medicine Journal - Wiley Online Library
Managing Pain in Active or Well-Controlled Systemic Lupus Erythematosus
Managing Pain in Active or Well-Controlled Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE) - Cancer Therapy Advisor
Table 1 from Anti-nucleosome antibodies in patients with systemic lupus erythematosus: potential utility as a diagnostic tool and disease activity marker and its comparison with anti-dsDNA antibody. | Semantic Scholar
AVISE CTD - Advanced Diagnostic Test for SLE and Autoimmune Disease
A Review of Complement Activation in SLE | SpringerLink
Inflammation associated anemia and ferritin as disease markers in systemic lupus erythematosus – topic of research paper in Clinical medicine. Download scholarly article PDF and read for free on CyberLeninka open science
High-Density SNP Screening of the Major Histocompatibility Complex in Systemic Lupus Erythematosus Demonstrates Strong Evidence for Independent Susceptibility Regions | PLOS Genetics
New SLE classification criteria reset disease definition | MDedge Rheumatology
Novel biomarkers in diagnosis of SLE [11] Biomarker Used As marker of... | Download Table
AVISE SLE Prognostic Test
Systemic Lupus Erythematosus | NEJM
First trimester markers in the SLE and non-SLE groups | Download Scientific Diagram
Frontiers | Emerging Molecular Markers Towards Potential Diagnostic Panels for Lupus
The Study of CD 69 as an Early Marker of SLE Activity in Pediatrics - SciAlert Responsive Version
Hypophosphatemia and Hyponatremia in Systemic Lupus Erythematosus Patients and Its Relation to Clinical Characteristic and Dise
A nationwide study of SLE in Japanese identified subgroups of patients with clear signs patterns and associations between signs and age or sex - C Terao, R Yamada, T Mimori, K Yamamoto,
Systemic Lupus Erythematosus | NEJM
Longitudinal Variation of Proteomic Biomarkers That Correlate with Efficacy Endpoints: Results from a Phase 3 Trial of Anifrolumab in Moderate to Severe Systemic Lupus Erythematosus - ACR Meeting Abstracts
PDF] Predictors of outcome and immunological markers in patients with Systemic lupus erythematosus | Semantic Scholar